Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Sven Plein
The session was opened with a presentation on the physiological concepts underpinning CMR stress testing. Dr. Almeida described the two principal methods in common use - Dobutamine stress CMR (DSMR) and vasolidator-stress myocardial perfusion stress CMR (Perfusion-CMR). In the context of the ischaemic cascade, perfusion-CMR is expected to detect earlier pathology, but DSMR in particular when combined with strain analysis offers a highly accurate alternative. Dr Kelle presented further data for the clinical use of DSMR, focusing in particular on the long-term prognostic value of the method. Showing data of a recent large two-centre study involving over 3,000 patients, he demonstrated that DSMR offers incremental value over other scar imaging alone and provides a “warranty period” with low cardiovascular risk of at least 3 years. Dr. Husser's presentation focused on the value of a combined assessment of myocardial perfusion and wall motion during dipyridamole CMR. He presented data from a recent multi-centre registry of over 1,500 patients, which showed that patients who develop a wall motion abnormality during dipyridamole stress had significantly worse outcome than patients with perfusion defects only. Interestingly, patients with a perfusion defect but without inducible wall motion abnormalities had a similar outcome as patients with normal perfusion. In a subsequent discussion, it was suggested that this observation likely reflected a larger ischaemia burden in the patients with inducible wall motion abnormalities. The final presentation was given by Dr Schwitter, who demonstrated in a number of case examples how CMR can be used in patients with complex coronary artery disease. In clinical practice, CMR is used to guide treatment choices by identifying fully infarcted and ischaemic myocardial territories. It was noted, however, that data from prospective clinical studies was needed to better inform such decisions. The session chairs, Dr. Rademakers and Dr. Plein, concluded an interesting and comprehensive session that presented the whole spectrum of CMR stress testing and an impressive amount of emerging outcome data for CMR.
Stress cardiovascular magnetic resonance (CMR) in coronary heart disease